The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CAMBRIDGE/TORONTO - Biogen Inc. (NASDAQ:BIIB) announced Monday a research collaboration with Dayra Therapeutics to discover and develop oral macrocyclic peptides targeting immunological conditions.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The partnership between Biogen ...
Biogen Inc. struck a deal with a biotech startup to research immune disorder treatments, part of an expansion of its immunology pipeline and a diversification away from risky neuroscience drugs.
The Biogen/Dayra partnership is driven by the strategic potential of oral macrocyclic peptides. This emerging therapeutic approach aims to deliver biologic-like efficacy and safety in a convenient ...
Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral format Collaboration further advances Biogen’s immunology strategy by broadening its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Biogen Inc, a global leading biotechnology company, and Dayra Therapeutics, a pioneering the development of oral macrocyclic peptide therapeutics to treat a range of human diseases, announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results